Erman Akkus, Medical Oncology Fellow at Ankara University, shared an article Nicolas Cabrit and colleagues authored on X:
“DFS as surrogate for OS in neoadjuvant treatment of esophageal cancer
Patient level
CS vs S: 0.73
CRS vs S: 0.76
CRS vs CS: 0.87
Trial level
CS vs S: 0.95
CRS vs S: 0.96
CRS vs CS: 0.93
PS: ORR did not seem to be a good surrogate in trials of GE cancers.”
Authors: Nicolas Cabrit et al.
